Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

FOLFOX-HAIC

Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times

DRUG

Camrelizumab

Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.

DRUG

Apatinib

Apatinib was administered orally 250mg once per day

Trial Locations (1)

510060

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

First People's Hospital of Foshan

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Affiliated Hospital of Guangdong Medical University

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

lead

Sun Yat-sen University

OTHER